Home > Insider Trading > Filing (0001415889-24-019488)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1999480	Alto Neuroscience Inc.	ANRO	Pharmaceutical Preparations (2834)	834210124

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
2008707	Adam Savitz	C/O Alto Neuroscience, Inc. 369 South San Antonio Road Los Altos CA 94022	Chief Medical Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-07-09	10,681	$12.53	35,532	No	4	P	Indirect	By Trust
Common Stock	Acquisiton	2024-07-09	1,388	$13.15	36,920	No	4	P	Indirect	By Trust
Common Stock	Acquisiton	2024-07-10	2,931	$13.22	39,851	No	4	P	Indirect	By Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Trust
No	4	P	Indirect	By Trust
No	4	P	Indirect	By Trust

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.05 to $13.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The shares are directly held by Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz (the "Friedman Trust"). The spouse of the Reporting Person is the beneficiary of the Friedman Trust, and the Reporting Person may be deemed to share beneficial ownership of the securities held by the Friedman Trust.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.04 to $13.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.